CD8A and neoplasm: Indeed, the ERK2 MAPK pathway is indispensable for CD8+ T cell survival after TCR activation (63), and MEKi represses the priming of Tnaive cells and the expansion of CD8+ TILs in the CT26-tumor-bearing mice, which was thought to impair CD8+ TILs antitumor effects (64).